Lobbying disclosures · Lobbying report
MRK: third_quarter 2026 lobbying report
Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues. Issues related to TrumpRX. Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21. Drug pricing proposals. Pharmacy Benefit Manager reform proposals. ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug prici
Follow MRK- Became public
- Oct 20, 2026, 5:02 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 7:37 PM EST
Why this is connected
Exact legal-name match: Merck & Co., Inc. (https://www.sec.gov/Archives/edgar/data/310158/).
Reported lobbying amounts
Income: $50,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/c065b286-c8dd-4af7-9d47-74230c4f8be6/","filing_uuid":"c065b286-c8dd-4af7-9d47-74230c4f8be6","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/c065b286-c8dd-4af7-9d47-74230c4f8be6/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Isabella Quinn","dt_posted":"2026-10-20T17:02:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 Pennsylvania Avenue, NW","registrant_address_2":"Suite 800","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":41454,"url":"https://lda.gov/api/v1/registrants/41454/","house_registrant_id":30771,"name":"WILLIAMS AND JENSEN, PLLC","description":"Lobbying Law Firm","address_1":"1201 Pennsylvania Avenue, NW","address_2":"Suite 800","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ISABELLA QUINN","contact_telephone":"+1 202-659-8201","dt_updated":"2026-07-30T10:41:36.640087-04:00"},"client":{"id":151341,"url":"https://lda.gov/api/v1/clients/151341/","client_id":3654,"name":"MERCK & CO INC","general_description":null,"client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues. Issues related to TrumpRX.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48784,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"B","last_name":"HOEKSTRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false},{"lobbyist":{"id":149999,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"BUTORA","suffix":null,"suffix_display":null},"covered_position":"Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":43332,"prefix":"mr","prefix_display":"MR.","first_name":"CHRISTOPHER","nickname":null,"middle_name":"W","last_name":"HATCHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false},{"lobbyist":{"id":149999,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"BUTORA","suffix":null,"suffix_display":null},"covered_position":"Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Drug pricing proposals. Pharmacy Benefit Manager reform proposals. ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug pricing proposals.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":48784,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"B","last_name":"HOEKSTRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP. Issues related to China WRT the BINSA bill.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false},{"lobbyist":{"id":149999,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"BUTORA","suffix":null,"suffix_display":null},"covered_position":"Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Issues related to China WRT the BINSA bill.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in MRK
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Oct 2, 2026 · disclosed Nov 5, 2026 · Dependent
- Oct 7, 2026$1K–$15K
Rep. Maria Elvira Salazar (R-FL-27)
Sold (partial) Merck & Co. MRK
$1K–$15K · Traded Sep 24, 2026 · disclosed Oct 7, 2026
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Sep 9, 2026$15K–$50K
Rep. Maria Elvira Salazar (R-FL-27)
$15K–$50K · Traded Aug 19, 2026 · disclosed Sep 9, 2026
- Sep 9, 2026$15K–$50K
Rep. Maria Elvira Salazar (R-FL-27)
$15K–$50K · Traded Aug 19, 2026 · disclosed Sep 9, 2026
- Jul 21, 2026$15K–$50K
Sen. Alan Armstrong (R-OK)
$15K–$50K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 30, 2026$1K–$15K
Rep. Keith Self (R-TX-3)
$1K–$15K · Traded Jan 10, 2025 · disclosed Jun 30, 2026 · filed 536 days later
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.